Windtree Therapeutics plans to buy up to $700 million worth of BNB, the fifth-largest cryptocurrency, following its recent all-time high price. The Nasdaq-listed biotech firm is raising funds through a $500 million equity line of credit and a $20 million stock purchase agreement. This initiative aims to bolster Windtree's balance sheet and follows a trend where publicly traded companies invest in cryptocurrencies to enhance stock value. Recently, BNB reached a peak of $808, before declining. Windtree's stock, despite a 5% drop on the day of the announcement, has seen a significant increase of 162% over the previous month. This move aligns with a growing trend of companies like Strategy and others that have begun acquiring digital assets, not limited to Bitcoin. Windtree's CEO emphasized that obtaining additional funding for BNB acquisition is crucial for the company’s strategy, indicating a shift towards integrating cryptocurrencies into corporate treasury management.

Source 🔗